Clinical Trial Update: Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

This entry reports an early-phase study evaluating CD38-CS1 CAR-T cells for refractory or recurrent multiple myeloma, sponsored by The Second Hospital of Shando…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CD38-CS1 CAR-T cells

Snippet

Sponsor: The Second Hospital of Shandong University | Conditions: ORR,OS,PFS | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING